| Primary |
| Acute Myeloid Leukaemia |
12.6% |
| Pneumonia |
12.6% |
| Pyrexia |
11.5% |
| Bronchopulmonary Aspergillosis |
7.6% |
| Hypertension |
6.0% |
| Infection |
6.0% |
| Lung Disorder |
5.4% |
| Septic Shock |
4.5% |
| Erysipelas |
3.5% |
| Febrile Bone Marrow Aplasia |
3.5% |
| Bacteraemia |
3.3% |
| Sepsis |
3.3% |
| Enterococcal Infection |
2.9% |
| Lung Infection |
2.7% |
| Prophylaxis |
2.7% |
| Anaesthesia |
2.5% |
| Anxiety |
2.5% |
| Pseudomonas Infection |
2.5% |
| Antibiotic Therapy |
2.3% |
| Bacterial Sepsis |
2.3% |
|
| Toxic Skin Eruption |
16.2% |
| Thrombocytopenia |
14.6% |
| Rash Maculo-papular |
7.7% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
5.4% |
| Rash Morbilliform |
5.4% |
| Renal Failure Acute |
4.6% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.8% |
| Pancreatitis Acute |
3.8% |
| Pyrexia |
3.8% |
| Septic Shock |
3.8% |
| Urticaria |
3.8% |
| Acute Generalised Exanthematous Pustulosis |
3.1% |
| Bone Marrow Failure |
3.1% |
| Hepatitis Toxic |
3.1% |
| International Normalised Ratio Increased |
3.1% |
| Prothrombin Time Prolonged |
3.1% |
| Rash |
3.1% |
| Skin Exfoliation |
3.1% |
| Tumour Lysis Syndrome |
3.1% |
| Cytolytic Hepatitis |
2.3% |
|
| Secondary |
| Product Used For Unknown Indication |
25.9% |
| Drug Use For Unknown Indication |
19.4% |
| Unevaluable Event |
6.9% |
| Pyrexia |
6.7% |
| Drug Exposure During Pregnancy |
4.8% |
| Lung Disorder |
4.5% |
| Acute Myeloid Leukaemia |
3.8% |
| Infection |
3.4% |
| Pneumonia |
3.2% |
| Antibiotic Therapy |
2.4% |
| Foetal Exposure During Pregnancy |
2.2% |
| Maternal Exposure Timing Unspecified |
2.2% |
| Bronchopulmonary Aspergillosis |
2.0% |
| Hypertension |
2.0% |
| Prophylaxis |
1.8% |
| Respiratory Tract Infection |
1.8% |
| Septic Shock |
1.8% |
| Sedation |
1.7% |
| Enterococcal Infection |
1.7% |
| Erysipelas |
1.7% |
|
| Thrombocytopenia |
11.7% |
| Toxic Skin Eruption |
11.3% |
| Renal Failure Acute |
10.6% |
| Neutropenia |
7.3% |
| Septic Shock |
5.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
5.1% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
4.7% |
| Tumour Lysis Syndrome |
4.7% |
| Agranulocytosis |
4.4% |
| Skin Exfoliation |
4.4% |
| Pyrexia |
4.0% |
| Premature Baby |
3.6% |
| Acute Generalised Exanthematous Pustulosis |
3.3% |
| Rash |
3.3% |
| Cytolytic Hepatitis |
2.9% |
| Rash Morbilliform |
2.9% |
| Pancreatitis Acute |
2.6% |
| Rash Erythematous |
2.6% |
| Renal Failure |
2.6% |
| Staphylococcal Infection |
2.6% |
|
| Concomitant |
| Prophylaxis |
21.6% |
| Product Used For Unknown Indication |
20.6% |
| Aplastic Anaemia |
13.5% |
| Drug Use For Unknown Indication |
8.5% |
| Infection Prophylaxis |
6.0% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.8% |
| Antiviral Prophylaxis |
3.2% |
| Constipation |
3.1% |
| Hypertension |
2.9% |
| Anxiety Disorder |
2.6% |
| Pain |
2.2% |
| Acute Lymphocytic Leukaemia |
2.1% |
| Insomnia |
2.0% |
| Acute Myeloid Leukaemia |
1.7% |
| Anxiety |
1.3% |
| Pyrexia |
1.3% |
| Back Pain |
1.1% |
| Fluid Replacement |
0.9% |
| Haemorrhoids |
0.9% |
| Hyperthermia |
0.8% |
|
| White Blood Cell Count Decreased |
13.9% |
| Thrombocytopenia |
12.4% |
| Renal Failure Acute |
8.6% |
| Renal Failure |
7.2% |
| Toxic Skin Eruption |
5.7% |
| Pancytopenia |
5.3% |
| Septic Shock |
5.3% |
| Pancreatitis Acute |
3.8% |
| Pyrexia |
3.8% |
| Rash Maculo-papular |
3.8% |
| Agranulocytosis |
3.3% |
| General Physical Health Deterioration |
3.3% |
| Sepsis |
3.3% |
| Stevens-johnson Syndrome |
3.3% |
| Toxicity To Various Agents |
3.3% |
| Liver Disorder |
2.9% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.9% |
| Weight Decreased |
2.9% |
| Cholestasis |
2.4% |
| Confusional State |
2.4% |
|
| Interacting |
| Drug Use For Unknown Indication |
22.5% |
| Lung Disorder |
20.0% |
| Pancytopenia |
15.0% |
| Pyrexia |
10.0% |
| Urinary Tract Infection |
7.5% |
| Chronic Obstructive Pulmonary Disease |
5.0% |
| Hypertension |
5.0% |
| Thrombosis Prophylaxis |
5.0% |
| Anaemia |
2.5% |
| Depression |
2.5% |
| Fungal Infection |
2.5% |
| Oral Fungal Infection |
2.5% |
|
| International Normalised Ratio Increased |
57.1% |
| Subdural Haematoma |
42.9% |
|
